FDA, Moderna appear aligned on mRNA flu shot heading into adcomm

FDA Advisory Committee to Review Moderna's mRNA Flu Vaccine

Moderna's seasonal mRNA flu vaccine, mRNA-1010 (mFLUSIVA), is set for review by the FDA's Vaccines and Related Biological Products Advisory Committee on June 18, 2026. This follows an initial refusal-to-file letter in February, which the FDA later reversed, allowing the application to proceed with a narrowed focus on specific age groups. Documents indicate a softening stance from the regulator, with alignment appearing to be reached. Moderna is seeking full approval for adults aged 50-64 and accelerated approval for those 65 and older, requiring a post-marketing study for the latter. The FDA noted no major efficacy deficiencies, with studies meeting success criteria, and no major safety issues or imbalances in adverse events. However, concerns remain regarding data from a single flu season, lack of efficacy data in immunocompromised individuals, and the short six-month safety follow-up.

• Moderna initially faced an FDA refusal-to-file for mRNA-1010 in February due to concerns about not using a high-dose comparator for older populations. The FDA subsequently reversed this decision, allowing the application to proceed with a narrowed scope. Ahead of the June 18 advisory committee meeting, regulatory documents suggest the FDA has softened its stance, indicating a potential alignment with Moderna's application for its seasonal flu vaccine.
• The FDA's review documents indicate that mRNA-1010's immunogenicity data supports efficacy in individuals over 65, and the vaccine demonstrated superior relative efficacy compared to a standard-dose comparator in patients aged 50 to 64. Crucially, the regulator identified no major safety issues or imbalances in adverse events or deaths between treatment and control groups, with studies meeting all prespecified sequential success criteria.
• Despite positive findings, the FDA flagged several uncertainties for the advisory committee, including that available data is from only one flu season, efficacy has not been established in immunocompromised or very frail older adults, and the six-month safety follow-up is relatively short for detecting rare adverse events. Moderna has proposed a bifurcated approval approach, including a promised confirmatory study for the older population, to address these concerns.
• The approval of mFLUSIVA is critical for Moderna's ambitious goal of launching over seven products by 2027-2028 and achieving a 10% year-over-year revenue increase to $1.9 billion in 2026. The mRNA-1010 vaccine represents a potential $1 billion revenue opportunity, vital for the company's aim to break even by 2028, a target previously jeopardized by the initial FDA refusal-to-file letter.

FDA's Assessment of mFLUSIVA's Efficacy and Safety

The FLU HERO study evaluated mRNA-1010, Moderna's quadrivalent seasonal influenza vaccine, in adults aged 18 years and older. In terms of efficacy, mRNA-1010 demonstrated hemagglutination inhibition (HAI) seroconversion rates that met non-inferiority criteria against licensed comparator influenza vaccines across all four strains (H1N1, H3N2, B/Yamagata, B/Victoria). Safety data indicated the vaccine was generally well tolerated, with solicited adverse reactions predominantly consisting of transient, mild-to-moderate injection site pain, fatigue, and headache — a reactogenicity profile consistent with other mRNA-based platforms.

The COVE-related influenza substudy and the pivotal Phase 3 trial of mFLUSIVA (mRNA-1010) further assessed immunogenicity and safety across broader adult populations, including older adults aged 65 and above — a group of particular clinical interest given their heightened vulnerability to severe influenza. Seroconversion rates and geometric mean titer (GMT) ratios were evaluated as co-primary endpoints. The vaccine met FDA immunological bridging criteria, with GMT responses demonstrating non-inferiority to standard-dose and high-dose comparators. Notably, no vaccine-related serious adverse events were identified, and rates of unsolicited adverse events were comparable between treatment and control arms.

From a regulatory standpoint, the FDA's review of these studies formed a key basis for evaluating mFLUSIVA's benefit-risk profile. The agency scrutinized both the immunogenicity endpoints — recognizing HAI titers as an accepted surrogate for protection — and the safety database for signals of concern, including myocarditis and pericarditis given the mRNA modality. Across the reviewed trials, no meaningful safety signals beyond the expected reactogenicity profile were identified, supporting a favorable assessment of the vaccine's overall benefit-risk balance in eligible adult populations.

Addressing Unmet Needs in Older Adult Flu Vaccination

Despite advances in seasonal influenza vaccine development, significant gaps in coverage and policy infrastructure persist across multiple geographies, leaving high-risk populations inadequately protected. The post-pandemic period has further complicated the epidemiological landscape, with influenza positivity rates surpassing pre-pandemic levels and shifting age-distribution patterns demanding updated immunization strategies.

• Low vaccination coverage among older adults globally: In China (2019–2021), influenza vaccination rates among adults aged ≥60 years were only 2.96–6.29% in urban areas and 1.29–2.94% in rural areas — far below WHO targets. In Pudong New Area, Shanghai (2013–2023), the overall average influenza vaccine coverage rate was just 2.27% (95% CI: 2.26–2.28), with the 20–24 age group recording the lowest coverage at 0.32% (95% CI: 0.31–0.33).

• Policy gaps in WHO South-East Asia Region (SEAR): As of October 2022, only three SEAR countries — India, Bhutan, and Thailand — had established seasonal influenza vaccination policies. The region's varied climatic conditions and insufficient local burden data continue to obscure the true epidemiological impact, contributing to persistently low vaccine uptake across member states.

• Suboptimal healthcare worker (HCW) vaccination: In China, only 19.65% of HCWs reported receiving at least one influenza vaccination in the past two years, with rates declining significantly between 2022 and 2023 — representing a critical occupational exposure and nosocomial transmission risk.

• Pediatric vulnerability and post-pandemic age-distribution shifts: Children under five exhibited the highest influenza-like illness (ILI) case burden. A post-pandemic shift was observed in China, with the mean age of infected children increasing by 1.4 years (95% CI: 1.2–1.7), trending toward school-aged children (6–17 years). B/Victoria infections showed renewed susceptibility among infants, with positivity rates of 11.0% (95% CI: 5.1–19.8) in the 0–5 month group versus 2.8% (1.9–4.0) in the 6–35 month group (p = 0.00014).

• Persistent barriers to uptake across high-risk groups: In Qatar, low coverage rates among children, the elderly, and pregnant women persist despite annual campaigns and free vaccine availability. Key barriers include vaccine hesitancy, limited public awareness, logistical challenges, and gaps in healthcare provider education. In Jordan, 73.1% of the population remained unvaccinated during the COVID-19 pandemic period, with 41.3% not perceiving influenza as a significant threat.

• Geographic and socioeconomic disparities: Vaccination rates in eastern China are consistently higher than in central and western regions, and urban coverage uniformly exceeds rural coverage across all vaccine types — highlighting structural inequities that targeted outreach programs have yet to adequately address.

• Increased severity risk from post-pandemic co-infections: Influenza peak activity in the post-pandemic period was approximately 10-fold higher than during the intra-pandemic period. Elevated bacterial co-detection rates — including Streptococcus pneumoniae (aOR = 1.52, 95% CI: 1.22–1.91) and Haemophilus influenzae (aOR = 1.46, 95% CI: 1.19–1.80) — point to heightened potential for severe respiratory co-infections in vulnerable populations.

• Data and infrastructure gaps in lower-resource settings: Bangladesh lacks a national seasonal influenza vaccination strategy despite WHO guidance, with limited cost-effectiveness data and no established framework to assess vaccine acceptability among high-risk groups. Comprehensive safety and immunogenicity data for quadrivalent influenza vaccines in Indian populations similarly remain limited, constraining evidence-based policy development.

mFLUSIVA's Position in the Evolving Flu Vaccine Market

Published evidence comparing investigational and standard-of-care influenza therapies spans antiviral agents, vaccine formulations, and prophylactic regimens, with the most clinically actionable data emerging from direct head-to-head trials. In pediatric populations, baloxavir marboxil has been evaluated against oseltamivir in the MiniSTONE-2 trial (n=173, ages 1–<12 years), where median time to symptom alleviation was 138.1 hours (95% CI: 116.6–163.2) with baloxavir versus 150.0 hours (95% CI: 115.0–165.7) with oseltamivir — a numerically favorable but statistically modest difference. A subsequent meta-analysis of five studies encompassing 2,261 pediatric patients confirmed that baloxavir significantly reduced fever duration compared to oseltamivir (mean difference: −13.49 hours, 95% CI: −23.75 to −3.24), though no significant difference was observed in time to overall symptom resolution. Baloxavir also demonstrated a more favorable gastrointestinal tolerability profile — 10.4% versus 17.2% for nausea/vomiting — and offers a meaningful adherence advantage through its single-dose oral regimen compared to oseltamivir's five-day twice-daily course.

In hospitalized adult populations, oseltamivir's benefit over standard of care has been quantified through a secondary analysis of the RETOS trial (n=691), employing causal machine learning methods. Patients with laboratory-confirmed influenza treated with oseltamivir demonstrated a 26% lower risk of clinical failure (95% CI: 3.2–48.0%), where clinical failure was defined as a composite of no clinical improvement within seven days, ICU transfer within 24 hours of admission, or rehospitalization or death within 30 days. These findings reinforce guideline-aligned recommendations to initiate antiviral therapy promptly upon confirmed or suspected influenza diagnosis in hospitalized patients. Among other neuraminidase inhibitors, laninamivir octanoate demonstrated superior efficacy to repeated oseltamivir dosing in murine models of lethal influenza infection, with a single administration showing comparable or greater benefit — though human data remain limited. Zanamivir, in nursing home prophylaxis studies, demonstrated comparable effectiveness to rimantadine in preventing laboratory-confirmed influenza during both influenza A and B outbreaks, with only rare breakthrough infections in either arm.

On the vaccine side, inactivated parenteral formulations have demonstrated well-characterized but variable efficacy across seasons. A Cochrane review of 38 clinical trials (n=66,248 healthy adults aged 16–65) found inactivated vaccines to be 80% efficacious (95% CI: 56–91%) against influenza when the vaccine matched the circulating strain under high-circulation conditions, falling to 50% (95% CI: 27–65%) under mismatch conditions, with an overall effectiveness of 30% (95% CI: 17–41%) against influenza-like illness. A randomized double-blind trial of trivalent inactivated vaccine (TIV) across the 2005–2007 seasons reported 63.2% point-estimate efficacy against all laboratory-confirmed influenza, though the primary endpoint against vaccine-matched, culture-confirmed cases (46.3%) did not meet the pre-specified success criterion of a one-sided 97.5% CI lower bound exceeding 35%, attributable in part to very low attack rates and a lineage mismatch for influenza B in 2005–2006. Quadrivalent live-attenuated influenza vaccine (Q/LAIV) in Japanese children aged 7–18 years achieved 100% efficacy against matched strains but only 27.5% (95% CI: 7.4–43.0) against all circulating strains, failing its primary endpoint while demonstrating an acceptable safety profile comparable to placebo.

mRNA-1010: Navigating the Path to a New Flu Vaccine Era

The upcoming FDA advisory committee meeting for Moderna's mRNA-1010 (mFLUSIVA) signals a critical juncture for the future of seasonal influenza vaccination. This event is more than just another vaccine review; it represents a significant stride for the mRNA platform into a well-established, yet often challenging, infectious disease market. The FDA's decision to proceed with the application, even with a narrowed focus on adults aged 50 and older, underscores the potential regulators see in this novel technology.

Clinical trials have consistently demonstrated that mRNA-1010 elicits robust immune responses, particularly strong hemagglutination inhibition (HAI) titers against influenza A strains, often outperforming traditional comparators, while showing comparable responses for influenza B. This immunogenicity, combined with the inherent speed and flexibility of mRNA manufacturing, positions mRNA-1010 as a potential game-changer, capable of offering broader protection against co-circulating B lineages and adapting more rapidly to emerging strains.

However, the path forward is not without its complexities. Key considerations highlighted by the FDA and supported by existing literature include:

• Single-season data: The current data largely stems from one flu season, raising questions about how mRNA-1010 will perform against the diverse and often unpredictable antigenic shifts of future seasons.

• Immunocompromised populations: A notable gap exists in efficacy data for immunocompromised individuals, a group highly vulnerable to severe influenza outcomes and known to have suboptimal responses to conventional vaccines.

• Long-term safety and reactogenicity: While mRNA-1010 has shown an acceptable safety profile, mRNA vaccines generally exhibit higher rates of mild-to-moderate reactogenicity compared to traditional vaccines. The relatively short six-month safety follow-up necessitates vigilant post-marketing surveillance.

Moderna's strategy to pursue full approval for adults 50-64 and accelerated approval for those 65 and older, contingent on a post-marketing study, reflects a pragmatic approach to market entry. This dual pathway allows for immediate impact in a high-priority demographic while providing time to gather extensive data for the older, often more vulnerable, population. Ultimately, the success of mRNA-1010 could not only secure Moderna a significant foothold in the influenza market but also further solidify the mRNA platform's role in addressing a wide array of infectious diseases, paving the way for future innovations.